In 2023, we also completed several initiatives to improve our credit profile and de-risk our capital structure. As you know, we divested our travel health business, generating up to $380 million of proceeds, extended the maturity of our secured credit facility to May 2025, implemented actions to save over $160 million of annualized operating expense, and announced a strategic shift to focus on our products business.

Mar 6, 2024 / CFO / receipt, needs a key / Rich Lindahl, CFO | earnings call 2024-03-06 | transcript 08fc61fa-6343-475b-9c5c-4c1b423dce19 | chars 16362-16781 | segment 16

Throughout 2023, we've taken significant steps to strengthen our financial position and de-risk the business. We have executed the travel health divestiture, implemented actions to save over $160 million of annualized operating expense, and announced a strategic shift to de-emphasize our CDMO business as a source of growth.

Nov 2, 2023 / receipt, needs a key / Rich Lindahl, EVP and Chief Financial Officer | earnings call 2023-11-02 | transcript a3c43158-a69b-428b-88a3-5dd16d3371ed | chars 16674-16999 | segment 16

First, as Bob noted, we anticipate closing on the divestiture of the travel health business in the second quarter. which will provide an infusion of upfront cash while furthering our stated objective of sharpening our strategic focus. The impact of the sale is now incorporated into our updated guidance for 2023 and enables us to better align our cost structure with our current revenue trajectory.

May 9, 2023 / CFO / receipt, needs a key / Rich Lindahl, CFO | earnings call 2023-05-09 | transcript 89444fcb-fd56-4aab-b42e-92dd60dd460d | chars 13845-14244 | segment 13

smallpox MCM sales of $235 to $255 million, other product sales of $165 to $185 million, CDMO services revenues of $115 to $135 million, adjusted net loss of $30 to $80 million, adjusted EBITDA of $75 to $125 million, and adjusted gross margin 41 to 44 percent this full year 2023 forecast reflects the following key considerations it excludes the potential impact of the sale of our travel health business we will update our guidance accordingly after the transaction closes which is anticipated in the second quarter it assumes the over-the-counter launch of Narcan by the end of the summer with continued strong demand in the US public interest channel as well as continuing demand in Canada continued procurement and delivery of anthrax, smallpox, and other medical countermeasure products to the U.S. and allied governments, and continued rebaselining of the CDMO services business overall and the impact of reduced production output from the Camden facility.

Feb 27, 2023 / CFO / receipt, needs a key / Rich Lindahl, CFO | earnings call 2023-02-27 | transcript 802ffaca-7841-437c-8d8f-e7f6a00e9f55 | chars 20696-21660 | segment 20

The position elimination and other actions we announced earlier in the year, in combination with the sale of our travel health business, will better align our cost structure with our revenue trajectory as we continue to strengthen quality and compliance and operationalize the network investments made over the past three years.

Feb 27, 2023 / CFO / receipt, needs a key / Rich Lindahl, CFO | earnings call 2023-02-27 | transcript 802ffaca-7841-437c-8d8f-e7f6a00e9f55 | chars 12044-12372 | segment 12